Cardiovascular Diseases

Carotid Revascularization Does Not Improve Cognition in Asymptomatic Severe Carotid Stenosis

In patients with severe asymptomatic carotid artery stenosis, carotid revascularization—either carotid artery stenting (CAS) or carotid endarterectomy (CEA)—added to intensive medical management (IMM) did not significantly improve cognitive function compared with IMM alone over up to 4 years. The CREST-2 randomized clinical trials included 2,366 US patients, of whom 2,165 underwent cognitive assessments using five tests covering learning, memory, executive function, attention, and processing speed. At 4 years, the adjusted difference in composite cognitive scores between CAS + IMM and IMM alone was 0.03 SD, while the difference between CEA + IMM and IMM alone was 0.02 SD, with no significant benefit in any individual cognitive domain. A separate CREST-2 substudy further examined whether patients with impaired cerebral blood flow might benefit more from revascularization. Among participants with reduced baseline cognition, revascularization provided no significant cognitive advantage over IMM alone, and the degree of baseline cerebral hemodynamic impairment did not modify the treatment effect. Together, these findings suggest that, in chronic asymptomatic severe carotid stenosis, revascularization does not improve cognitive function, even among patients with evidence of cerebral hemodynamic impairment. Source: https://jamanetwork.com/

hyangiu

Recent Posts

Intensive BP Control Reduces Cardiovascular Events After Ischemic Stroke

Targeting a systolic blood pressure (BP) of less than 120 mm Hg lowered the incidence…

20 hours ago

No Significant Reduction in Major Cardiovascular Events with Intensive BP Lowering in T2D

In patients with type 2 diabetes (T2D) and high cardiovascular risk, targeting a systolic blood…

20 hours ago

Stopping Statins Noninferior to Continuing Them in Older Adults without Known CVD

Among older adults with at least two chronic conditions but no known cardiovascular disease, discontinuing…

22 hours ago

Ziltivekimab and Pelacarsen Show No Clinical Benefit Despite Effective Biomarker Lowering

Two randomized, placebo-controlled trials of targeted therapies—ziltivekimab, a monoclonal antibody neutralizing interleukin-6, and pelacarsen, an…

2 days ago

Cold Drives Heart Failure Hospitalizations in Older US Adults

Among US Medicare beneficiaries, colder ambient temperatures were associated with increased heart failure hospitalizations while…

6 days ago

No Significant Difference Between Initial CTO-PCI and No CTO-PCI Strategies in 10-Year Follow-Up

In the 10-year extended follow-up of the DECISION-CTO trial, an initial strategy of percutaneous coronary…

6 days ago

This website uses cookies.